Recently, PON1 AREase and POase activity has been assayed in a cohort of women with breast cancer treated with doxorubicin (DOX) to determine whether there is any association with cancer therapy-related cardiac dysfunction development (CTRCD) [221]. This evidence concerns the gene PON1 and cancer.